Rapport, a clinical-stage neuroscience biotech, files for IPO

Rap­port Ther­a­peu­tics, which emerged out of John­son & John­son’s neu­ro­science unit last year, has sub­mit­ted its pitch for a Nas­daq list­ing.

The Boston-based start­up plans to trade as “RAPP” and didn’t dis­close how much it plans to raise, ac­cord­ing to a Fri­day evening SEC fil­ing.

It would be the third neu­ro­science drug de­vel­op­er to go pub­lic this year, along with Con­tineum Ther­a­peu­tics and Al­to Neu­ro­science, fol­low­ing grow­ing in­ter­est by in­vestors in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.